Bankinter: Ebglyss (lebrikizumab) receives positive opinion from the European Medical Agency's advisory committee. The Target Price is raised from €9.50/share
Mike Gallup, CEO of Norstella, Evaluate’s parent company said: “Key assumptions that have underpinned the pharmaceutical sector for so long – for example, the US market’s supreme profitability and reliance on big M&A to fuel growth – are being tested. “The far-reaching Inflation Reduction Act (IRA), combined with .